Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-Coinfected subjects treated with interferon-based regimens

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 712-719

  Sherman, Kenneth E ^a   Rouster, Susan D ^a   Stanford, Sandra ^a   Blackard, Jason T ^a   Shire, Norah ^b   Koziel, Margaret ^c   Peters, Marion ^e   Chung, Raymond T ^d  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETERODUPLEX ANALYSIS; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 76449101094     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650490     Document Type: Article

References (24)

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-497.
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
4. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216.
5. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
6. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-459.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-450.
8. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848.
9. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007; 14:239-248.
10. Sherman KE, Shire NJ, Rouster SD, et al. Viral ki netics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128:313-327.
11. Sherman KE, Andreatta C, O'Brien J, Gutierrez A, Harris R. Hepatitis C in human immunodeficiency virus-coinfected patients: increased variability in the hypervariable envelope coding domain. Hepatology 1996; 23:688-694.
12. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-344.
13. Farci P, Strazzera R, Alter HJ, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002; 99:3081-3086.
14. Qin H, Shire NJ, Keenan ED, et al. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005; 105:533-541.
15. Sherman K, Rouster S, Mendenhall C, Thee D. Hepatitis C RNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999; 30:265-270.
16. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991; 88: 2451-2455.
17. Neau D, Jouvencel AC, Legrand E, et al. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. JMed Virol 2003; 71:41-48.
18. Laskus T, Wilkinson J, Karim R, et al. Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART). Hepatology 2007; 46:359-370.
19. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
20. Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J 2008; 5:78.
21. Salmeron J, Casado J, Rueda PM, et al. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. J Clin Virol 2008; 41:264-269.
22. Ueda E, Enomoto N, Sakamoto N, et al. Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 2004; 29:89-96.
23. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. J Med Virol 1999; 58: 353-358.
24. McKechnie VM, Mills PR, McCruden EA. The NS5a gene of hepatitis C virus in patients treated with interferon-alpha. J Med Virol 2000; 60:367-378.